Free Consultation 215.567.2010

Caesar Rivise’s Diversity Shines Through in Victory for Generic Drug Manufacturers

Posted on Oct 18, 2018 in News

In an important victory for consumers, Judge Sheridan of the United States District Court for the District of New Jersey on October 12, 2018 issued an order invalidating U.S. Patents Nos. 8,673,927 and 9,173,859 for obviousness and obviousness-type double patenting.  The patents invalidated in this Hatch-Waxman litigation relate to methods of using the type II diabetes medications Tradjenta® and Jentadueto®.

The victory followed a two-week trial held in the Trenton, New Jersey courthouse.  Key to this victory was the work of Caesar Rivise’s team of Robert S. Silver, Lynn M. Terrebonne, Ph.D., Salvatore R. Guerriero and Pei-Ru Wey, Pharm. D.

Lynn Terrebonne, a pharmacologist, spearheaded the direct and cross examination of the medical invalidity experts.  Pei-Ru Wey, a pharmacist, and Sal Guerriero took lead on attacking the commercial success of the branded products with Ms. Wey conducting the cross-examination of the plaintiffs’ economics expert.

Learn more about our ANDA litigation group at our website,


1635 Market Street, 12th Floor
Philadelphia, Pennsylvania 19103-2212

215-567-2010 | 215-751-1142

View Map


King Street Plaza - Suite 304. 800 N. King Street
Wilmington, Delaware 19801

302-544-9100 | 302-544-9103

View Map

Lehigh Valley

2030 Tilghman Street, Suite 201A
Allentown, Pennsylvania 18104-4399

610-255-7551 | 610-255-7542

View Map